围术期他汀使用对肝细胞癌肝切除患者预后的影响:非慢性肝炎病毒感染亚组分析
该回顾性研究分析643例接受根治性肝切除术的肝细胞癌患者,其中204例为非乙非丙型肝炎亚组。围术期他汀使用者43例(6.7%)。
要点
- 围术期他汀使用与肝细胞癌肝切除患者无复发生存改善显著相关。
- 他汀使用与总生存无显著关联。
- 非乙非丙肝细胞癌亚组中他汀使用同样与无复发生存改善相关。
核心结论
- 围术期他汀使用与接受根治性肝切除术的肝细胞癌患者无复发生存改善相关。
研究设计与样本
- 回顾性分析643例接受根治性肝切除术的肝细胞癌患者,其中非乙非丙亚组204例。
- 围术期他汀使用者定义为术前接受他汀药物治疗且肝切除后累积限定日剂量>28。
主要发现
- 643例患者中43例(6.7%)接受围术期他汀治疗。
临床怎么用
- 对于接受肝切除术的肝细胞癌患者,围术期他汀使用可能改善无复发生存,但需结合个体情况评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins have been reported to reduce the risk of hepatocellular carcinoma (HCC). The effect of perioperative statin use on the prognosis of HCC patients undergoing liver resection remains unclear. METHODS: We retrospectively analyzed 643 patients who underwent curative liver resection for HCC. Patients negative for hepatitis B surface antigen and hepatitis C antibody were classified as the non-B non-C HCC subgroup (n = 204). Perioperative statin users were defined as patients preoperatively receiving statin medications and maintaining > 28 cumulative defined daily doses after liver resection. The recurrence-free survival (RFS) and overall survival (OS) according to statin use were analyzed in the overall HCC cohort or in the non-B non-C HCC subgroup. RESULTS: Among a total of 643 (HCC) patients, 43 patients (6.7%) received perioperative statin medications. In statin users, the proportion of non-B non-C HCC patients was significantly higher than in nonstatin users. Statin users had a high prevalence of obesity and diabetes, as well as dyslipidemia. The liver function of statin users was better than that of nonstatin users. The multivariate survival analysis revealed that use of statins was significantly associated with improvement of RFS (hazard ratio [HR], .42; 95% confidence interval [CI], 0.25-0.71; P = .001), but not with OS (HR, 0.62; 95% CI, 0.30-1.27; P = .19). In the subgroup analysis of the non-B non-C HCC cohort, statin use was significantly associated with improvement of RFS (HR, 0.47; 95% CI, 0.22-0.99; P = .04). CONCLUSION: Perioperative statin use was associated with an improvement of RFS in HCC patients undergoing curative liver resection.
引用
- Nishio T, Taura K, Nakamura N, et al. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection. Surgery. 2017. PMID: 29167018. doi:10.1016/j.surg.2017.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。